指南与共识重症综合管理与镇静镇痛消化、代谢与肾脏急症

接受连续性肾脏替代治疗的重症患者万古霉素暴露目标与个体化给药推荐

Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy.
指南 / 共识 · Pharmacotherapy · 2023-02-09
一句话结论作者推荐CRRT重症患者万古霉素初始剂量5–7.5 mg/kg q12h,AUC>427 mg·h/L(假定MIC=1 mg/L)为疗效暴露目标。

本研究基于大型公共数据库2017–2019年接受静脉万古霉素联合CRRT的成人重症患者数据,用180例患者的1186个观察点建立群体药代动力学模型,以贝叶斯法估算个体AUC,在159例可评估患者中分析临床疗效。结果显示CRRT强度显著影响万古霉素药代动力学,AUC>427 mg·h/L是临床疗效的唯一显著预测因素(校正OR 1.008,95%CI 1.004–1.011,P=0.000)。蒙特卡洛模拟推荐CRRT强度20–25 mL/kg/h者用5 mg/kg q12h、25.1–45 mL/kg/h者用7.5 mg/kg q12h作为初始方案。

要点

  • CRRT重症患者万古霉素疗效暴露目标:AUC>427 mg·h/L(假定MIC=1 mg/L),为临床疗效唯一显著预测因素(校正OR 1.008,95%CI 1.004–1.011,P=0.000)。
  • CRRT强度20–25 mL/kg/h者,蒙特卡洛模拟推荐万古霉素初始剂量5 mg/kg q12h。
  • CRRT强度25.1–45 mL/kg/h者,蒙特卡洛模拟推荐万古霉素初始剂量7.5 mg/kg q12h。
  • 协变量分析显示CRRT强度显著影响万古霉素药代动力学,个体化给药需按CRRT强度分层。

适用人群与场景

  • 数据库2017–2019年间接受静脉万古霉素联合CRRT治疗的成人重症患者;180例、1186个观察点纳入群体药代动力学模型建立,159例符合条件患者纳入临床疗效分析。

诊断标准与关键阈值

  • 万古霉素疗效暴露阈值:AUC>427 mg·h/L(假定MIC=1 mg/L),为预测临床疗效的阈值(ROC曲线确定)。

处置流程与药物剂量

  • CRRT强度20–25 mL/kg/h的患者:蒙特卡洛模拟推荐万古霉素初始剂量5 mg/kg q12h。
  • CRRT强度25.1–45 mL/kg/h的患者:蒙特卡洛模拟推荐万古霉素初始剂量7.5 mg/kg q12h。
  • 采用贝叶斯法基于个体万古霉素浓度估算AUC,以评估是否达到AUC>427 mg·h/L的暴露目标。

研究设计与关键结果

  • 回顾性观察性队列研究,基于大型公共数据库,180例患者1186个观察点建立群体药代动力学模型,159例符合条件患者分析临床疗效。
  • 协变量分析显示CRRT强度显著影响万古霉素药代动力学。
  • AUC>427 mg·h/L是临床疗效的唯一显著预测因素(校正OR 1.008,95%CI 1.004–1.011,P=0.000)。
  • 蒙特卡洛模拟推荐CRRT强度20–25 mL/kg/h者万古霉素5 mg/kg q12h,25.1–45 mL/kg/h者7.5 mg/kg q12h。

证据类型、等级与局限

  • 证据类型:回顾性观察性队列研究(基于大型公共数据库)。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,对接受CRRT的重症患者可以AUC>427 mg·h/L(假定MIC=1 mg/L)作为万古霉素疗效暴露目标,并按CRRT强度选择初始剂量:20–25 mL/kg/h用5 mg/kg q12h、25.1–45 mL/kg/h用7.5 mg/kg q12h。
  • 原文未据此给出其他推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

STUDY OBJECTIVE: Few studies have been conducted to quantify the exposure target of vancomycin in intensive care unit (ICU) patients undergoing continuous renal replacement therapy (CRRT) and provide optimized dosage regimens. We aimed to determine vancomycin exposure target and dosing recommendations using data from an open database in critically ill patients undergoing CRRT.

DESIGN: A retrospective observational cohort study.

DATA SOURCE: A large public database.

PATIENTS: The adult patients who received intravenous vancomycin and CRRT treatment in the database between 2017 and 2019 were reviewed to determine eligibility. A total of 180 patients with 1186 observations were included in the population pharmacokinetic (PPK) model development. The clinical efficacy of vancomycin was analyzed in 159 eligible patients.

METHODS: A PPK model was developed to estimate individual pharmacokinetic (PK) parameters. The area under the concentration-time curve (AUC) was estimated by a Bayesian approach based on individual vancomycin concentrations. Multivariate logistic regression analyses were performed to identify the factors of clinical outcomes. Threshold of vancomycin exposure in predicting efficacy was identified via receiver operating characteristic (ROC) curve. Dosing recommendations were designed using Monte Carlo Simulations (MCS) based on the optimized exposure target.

MEASUREMENTS AND MAIN RESULTS: On covariate analysis, CRRT intensity significantly affected vancomycin PK. The AUC above 427 mg*h/L was the only significant predictor of clinical efficacy (adjusted odds ratio (aOR): 1.008, 95% confidence interval (CI): 1.004-1.011, p = 0.000). MCS indicated that vancomycin dosage regimens of 5 mg/kg q12h or 7.5 mg/kg q12h were recommended for patients with CRRT intensities of 20-25 mL/kg/h or 25.1-45 mL/kg/h, respectively.

CONCLUSIONS: An AUC threshold of 427 mg*h/L (assuming the minimal inhibitory concentration (MIC) = 1 mg/L) was a recommended efficacy exposure target of vancomycin for critically ill patients undergoing CRRT. Vancomycin 5-7.5 mg/kg q12h is recommended as the initial dosage regimens for ICU patients undergoing CRRT.

来源:Pharmacotherapy,查看原文。版权归原作者所有。

参考来源

  1. Wang C, Chen J, Yang B, et al. Determination of vancomycin exposure target and individualized dosing recommendations for critically ill patients undergoing continuous renal replacement therapy. Pharmacotherapy. 2023. PMID: 36714991. doi:10.1002/phar.2771

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。